STRATEC SE

M&A Activity • Jul 18, 2007

News Details

Ad-hoc | 18 July 2007 07:44

STRATEC and Gen-Probe with major molecular diagnostics agreement

STRATEC Biomedical Systems AG / Agreement/Alliance

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

STRATEC and Gen-Probe with major molecular diagnostics agreement

STRATEC to automate Gen-Probe’s molecular diagnostics tests

Birkenfeld, July 18, 2007

Based on the authorization of Gen-Probe, dated July 17, 2007, to commence
development activities, STRATEC Biomedical Systems AG, Birkenfeld, Germany,
hereby announces an agreement with Gen-Probe Inc., San Diego, California,
USA, for the development and supply by STRATEC of fully automated analyzer
systems called 'Panther'. Gen-Probe is planning to market its own molecular
diagnostic tests, used primarily to diagnose human diseases and to screen
donated human blood, together with the 'Panther' analyzer systems as a
system solution on a worldwide basis.

During the development phase, which is scheduled to last three to four
years, STRATEC’s new business partner Gen-Probe will make milestone
payments expected to total to more than USD 15 million both for the
progress made in the development project and for the purchase of prototype,
validation, and pre-production instruments. Initial down-payments received
for the first phase of the development will be shown in STRATEC’s FY 2007
balance sheet.

In addition to the development agreement, the contract includes a supply
agreement with minimum purchase volumes scheduled over several years.
STRATEC expects to generate the first sales from the supply of analyzer
systems from 2009 onwards.

---

Information and Explaination of the Issuer to this News:

STRATEC’s Board of Management commented: 'The cooperation now initiated
with Gen-Probe represents our third OEM partnership in the field of
molecular diagnostics and documents our success in mapping our established
business model onto this market segment, one of the fastest growing in our
sector.'

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture
and marketing of rapid, accurate and cost-effective nucleic acid tests
(NATs) that are used primarily to diagnose human diseases and screen
donated human blood. Gen-Probe has more than 24 years of NAT expertise, and
received the 2004 National Medal of Technology, America's highest honor for
technological innovation, for developing NAT assays for blood screening.
Gen-Probe is headquartered in San Diego, California, USA, and employs
approximately 1,000 people. For more information, go to
http://www.gen-probe.com.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange and on other exchanges.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and its subsidiaries STRATEC Biomedical Inc., STRATEC
NewGen GmbH, Robion AG and Sanguin International Ltd., as well as Sanguin
International Inc., a subsidiary of Sanguin International Ltd.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 (0)7082 7916 190
Fax: +49 (0)7082 7916 999
E-Mail: ir@stratec-biomedical.de
DGAP 18.07.2007

---

Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf

End of News DGAP News-Service

---